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Abstract Epidemiological data suggest that the consumption
of polyphenol-rich foods reduces the incidence of cancer, cor-
onary heart disease, and inflammation. Chlorogenic acid
(CGA), an ester of caffeic and quinic acids, is one of the most
abundant polyphenol compounds in human diet with proven
biological effectiveness both in vitro and in vivo. The aim of
the study is to investigate the possible anti-inflammatory ef-
fect of CGA in the gastrointestinal (GI) tract and its mecha-
nism of action. We used a well-established model of colitis,
induced by int racolonic ( i .c . ) adminis t ra t ion of
trinitrobenzenesulfonic acid (TNBS) in mice. The anti-
inflammatory effect of CGA in the colon was evaluated based
on the clinical and macroscopic and microscopic parameters.
To investigate the mechanism of protective action of CGA,
myeloperoxidase (MPO), H2O2, and NF-κB levels were
assessed in the colon tissue. CGA administered i.c. at the dose
of 20 mg/kg (two times daily) protected against TNBS-
induced colitis more effectively than the same dose adminis-
tered orally (p.o.), as evidenced by significantly lower macro-
scopic and ulcer scores. Furthermore, CGA (20 mg/kg, i.c.)
reduced neutrophil infiltration, as demonstrated by decreased
MPO activity. Moreover, CGA suppressed activation of
NF-κB, as evidenced by lower levels of phospho-NF-κB/
NF-κB ratio in the tissue. CGA did not affect the oxidative
stress pathways. CGA exhibits anti-inflammatory properties
through reduction of neutrophil infiltration and inhibition of
NF-κB-dependent pathways. Our results suggest that CGA
may have the potential to become a valuable supplement in
the treatment of GI diseases.
Keywords Chlorogenic acid . Trinitrobenzenesulfonic
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Introduction
Inflammatory bowel diseases (IBDs), which include Crohn’s
disease (CD) and ulcerative colitis (UC), are chronic, relaps-
ing inflammatory disorders of the gastrointestinal (GI) tract.
Whereas the inflammation in UC affects only colonic mucosa,
in CD, it affects the entire gut wall and may occur in any part
of the GI tract (Podolsky 2002). Currently, the incidence and
prevalence of IBD are the highest in westernized nations
(Molodecky et al. 2012). However, considering that the inci-
dence of IBD is increasing, mortality is low, and the disease is
most often diagnosed in the young people, the prevalence of
IBD will continue to increase globally (Molodecky et al.
2012). Treatment with 5-aminosalicylates, immunosuppres-
sive agents, glucocorticosteroids, and biological therapies
are generally effective in IBD. However, the side effects and
economic costs, especially with biological therapy, cannot be
ignored. These facts, together with impaired patients’ quality
of life, imply that new therapeutics are needed.
The etiology of IBD remains largely unknown, but it is
considered to be related to a combination of genetic, microbi-
al, immunological, and environmental factors that results in an
inordinate and abnormal immune response in genetically
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vulnerable individuals. Recent studies highlight that both in-
nate and adaptive immune responses maintain the same im-
portance in development of gut inflammation (Zhang and Li
2014). However, apart from the presence of activated innate
immune response cells, such asmacrophages, neutrophils, and
monocytes, an excessive production of reactive oxygen spe-
cies (ROS) and pro-inflammatory mediators, including
TNF-α and interleukin (IL)-1, -6, and -8, plays a major role
in the pathogenesis of IBD (Babior 2000; Sun et al. 2013). Of
note, natural immunity, and also most types of inflammation,
is mediated by transcription nuclear factor κB (NF-κB)-relat-
ed pathways (Umezawa 2011). It has been shown that NF-κB
is strongly activated in patients with IBD, as well as in exper-
imental models of colitis (Atreya et al. 2008).
Chlorogenic acid (CGA), formed by esterification of
caffeic and quinic acids (Fig. 1), is one of the most abundant
polyphenols in nature (Suzuki et al. 2006). CGA widely oc-
curs in medicinal plants from Europe and Asia, for example,
honeysuckle, Angelicae sinensis Radix, and Chuanxiong
Rhizoma, as well as in coffee beans and apples (Hebeda
et al. 2011; Hulme 1953; Li et al. 2014a, b). Several studies
were conducted to investigate biological activities of CGA,
including its anti-bacterial, anti-carcinogenic, and anti-
oxidant effects in animal models of diseases (Kim et al.
2010; Lafay et al. 2006; Ruifeng et al. 2014); however, the
effect of CGA on the inflammatory reaction in the GI tract has
not been explored so far.
In search for novel therapeutics and supplements for treat-
ment of GI diseases, here we characterized the anti-
inflammatory action of CGA in experimental colitis in mice.
In particular, we were interested in the effect of CGA after
disparate routes of administration, as well as the involvement
of NF-κB-regulated pathways. The animal model of colitis
used in our experiments, induced by intracolonic (i.c.) admin-
istration of 2,4,6-trinitrobenzenesulfonic acid (TNBS), has
been chosen for this study because it closely mimics clinical
and morphological features of human CD (Elson et al. 1995).
Materials and methods
Animals
Male balbC mice were obtained from the Animal House at the
University of Lodz, Poland. All animals, weighing 22–28 g,
were housed at a constant temperature (22 °C) and maintained
under a 12-h light/dark cycle in sawdust-lined plastic cages
with free access to chow and tap water. All animal protocols
were approved by the Medical University of Lodz Animal
Care Committee (Protocol #670/2012).
Induction of colitis
Colitis was induced by i.c. administration of TNBS, as de-
scribed previously (Storr et al. 2009). Briefly, mice were light-
ly anesthetized with 1 % isoflurane (Baxter Healthcare Corp.,
IL, USA) and TNBS (4 mg in 0.1 mL of 30 % ethanol in
saline) was administered into the colon through a catheter
inserted 3 cm proximally to the anus. Previous experiments
showed that the dose of TNBS used in this study induced
reproducible colitis.
Pharmacological treatment
CGA was administered two times daily at the dose of
20 mg/kg orally (p.o., 150 μL) and i.c. (100 μL), with the first
treatment 30 min before the induction of colitis in acute colitis
model. In semi-chronic colitis model, CGAwas administered
two times daily at the dose of 20 mg/kg i.c. (100 μL) from day
3 to day 6. CGA was dissolved in 5 % dimethyl sulfoxide
(DMSO) in saline, which was used as vehicle. Control ani-
mals received vehicle alone. Briefly, mice were lightly anes-
thetized with 1 % isoflurane (Baxter Healthcare Corp., IL,
USA) and CGAwas administered into colon through a cath-
eter inserted 3 cm proximally to the anus.
Evaluation of colonic damage
Animals were killed by cervical dislocation 3 days after TNBS
application in acute colitis model and 7 days post-TNBS in
semi chronic colitis model. Colons were instantly removed,
opened longitudinally, washed with phosphate-buffered saline
(PBS), and immediately examined.Macroscopic colonic dam-
age was assessed using an established semi-quantitative scor-
ing system by adding individual scores for ulcer, colonic
shortening, wall thickness, and presence of hemorrhage, fecal
blood, and diarrhea, as described previously (Fichna et al.
2012; Sałaga et al. 2013, 2014b). For ulcer score and colonicFig. 1 Chemical structure of CGA
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shortening, the following scale was used: ulcer, 0.5 points for
each 0.5 cm; shortening of the colon, 1 point for >15 % and 2
points for >25 % (based on the mean length of the colon in
untreated mice of 8.07±0.20 cm, n=6). The wall thickness
was measured in millimeters with vernier caliper, and thick-
ness of n in mm corresponds to n scoring points. The presence
of hemorrhage, fecal blood, or diarrhea increased the score by
1 point for each additional feature. The macroscopic scoring
was performed in blind manner.
Histology
After macroscopic scoring, segments of the distal colon
were stapled flat, mucosal side up, onto cardboard and
fixed in 10 % neutral-buffered formalin for 24 h at
4 °C. Samples were then dehydrated, embedded in par-
affin, sectioned at 5 μm, and mounted onto slides.
Subsequently, sections were stained with hematoxylin
and eosin and examined using a Motic AE31 micro-
scope (Ted Pella, Redding, CA, USA). Photographs
were taken using a digital imaging system consisting
of a digital camera (Moticam 2300, Ted Pella,
Redding, CA, USA) and image analysis software
(MoticImages Plus 2.0, Motic Deutschland GmbH,
Wetzlar Germany). Microscopic total damage score was
determined in blind manner based on the presence
(score = 1) or absence (score = 0) of goblet cell deple-
tion, the presence (score = 1) or absence (score = 0) of
crypt abscesses, the destruction of mucosal architecture (nor-
mal = 1, moderate = 2, extensive = 3), the extent of muscle
thickening (normal = 1, moderate = 2, extensive = 3), and the
presence and degree of cellular infiltration (normal = 1, mod-
erate = 2, transmural = 3).
Determination of tissue myeloperoxidase activity
The method adapted by Fichna et al. (2012) was used
to assess granulocyte infiltration and to quantify the
myeloperoxidase (MPO) activity. Shortly, 1-cm seg-
ments of colon were weighed and homogenized in
hexadecytrimethylammonium bromide (HTAB) buffer
(0.5 % HTAB in 50 mM potassium phosphate buffer,
pH 6.0; 50 mg tissue/mL) immediately after isolation.
Homogenate was centrifuged (15 min, 13,200 rpm,
4 °C), and 7 μL of supernatant was added to each well
on a 96-well plate, containing 200 μL of 50 mM po-
tassium phosphate buffer (pH 6.0), supplemented with
0.167 mg/mL of O-dianisidine hydrochloride and
0.05 μL of 1 % H2O2. Absorbance was measured at
450 nm (iMARK Microplate Reader, Biorad, Hemel
Hempstead, Hertfordshire, UK). All measurements were
performed in triplicate. MPO was expressed in milliunits
per gram of wet tissue, 1 unit being the quantity of
enzyme able to convert 1 μmol of H2O2 to water in
1 min at room temperature. Units of MPO activity per
1 min were calculated from a standard curve using pu-
rified peroxidase enzyme.
Determination of tissue hydrogen peroxide levels
Assay was performed according to the methodology described
before by Sałaga et al. (2014a).
Briefly, 50 mg of colon tissue fragments was homog-
enized with 2 mL of 1.15 % potassium chloride. Then,
10-μL aliquots of tissue homogenate were mixed with
90 μL of PBS (pH 7.0) and 100 μL of horseradish
peroxidase (1 U/mL) containing 400 μmol homovanilic
acid (HRP+HVA assay) or with 90 μL of PBS and
100 μL of 1 U/mL horseradish peroxidase only (HRP
assay). Both homogenates were incubated for 60 min at
37 °C. Subsequently, 300 μL of PBS and 125 μL of
0.1 M glycine-NaOH buffer (pH 12.0) with 25 mM
EDTA were added to each homogenate sample.
Excitation was set at 312 nm and emission was mea-
sured a t 420 nm (Perk inElmer Luminescence
Spectrometer, Beaconsfield, UK). Readings were con-
verted into H2O2 concentration using the regression
equation Y=0.012X−0.007, where Y = H2O2 concentra-
tion in homogenate (μM) and X = intensity of light
emission at 420 nm for HRP+HVA assay reduced by
HRP assay emission (arbitrary units, AU). The regres-
sion equation was prepared from three series of calibra-
tion experiments with 10 increasing H2O2 concentrations
(range 10–1000 μM). The lowest H2O2 detection was
0.1 nM, with intra-assay variability not exceeding a
2 %.
Western blot analysis of NF-κB protein levels
Shortly, the tissue was minced and homogenized with the
use of a motor-driven Potter homogenizer in 10 volumes
of lysis buffer. Concentration of total protein pool was
evaluated in each sample using modified Lowry protocol
(Cadman et al. 1979). Separation of proteins (30 μg/well)
was performed on 7.5 % SDS-PAGE gel in electrophoretic
buffer. Electrophoretically separated proteins were
electroblotted using Immobilon P membranes (pore size,
0.45 μm) in transfer buffer. The membranes were incubat-
ed for 1 h at room temperature in 3 % non-fat dry milk
Tris-buffered saline with Tween 20 (0.05 %) to saturate
non-specific protein binding sites (Stawinska et al. 2008).
The membranes were probed with the following primary
antibodies (Santa Cruz Biotechnology, Paso Robles, CA,
USA) overnight at 4 °C: anti-rabbit anti-mouse p65
(1:4000) and pp65 (1:5000) and β-GAPDH (1:3000) as
reference protein. Appropriate horseradish-peroxidase-
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conjugated secondary antibodies were applied for 1 h at
room temperature, and then the bands were visualized
using a 3,3′,5,5′-12 tetramethylbenzidine (TMB) as a sub-
strate for the localization of HRP activity. Qualitative and
quantitative analysis was performed by measuring integrat-
ed optical density (OD) by GelProAnalyzer ver. 3.0 for
WindowsTM program (Media Cybernetics, Warrendale,,
PA, USA).
Drugs
All drugs and reagents, unless otherwise stated, were pur-
chased from Sigma-Aldrich (Poznan, Poland). CGA (purity
98 % by high-performance liquid chromatography) was ex-
tracted from honeysuckle flowers and purchased from
Nanjing Zelang Medical Technology Co. (Nanjing, Jiangsu,
China) by one of the authors (C.C.). In all in vivo tests, drugs
were dissolved in 5 % DMSO in saline, which was used as
vehicle in control groups. Vehicle affected none of the mea-
sured parameters when given alone.
Statistics
Statistical analysis was performed using Prism 5.0 (GraphPad
Software Inc., La Jolla, CA, USA). The data are expressed as
means±SEM. One-way ANOVA followed by Newman-
Keuls post hoc test was used for analysis. P values <0.05 were
considered statistically significant.
Results
Intracolonic administration of CGA attenuates acute
TNBS-induced colitis in mice
The i.c. instillation of TNBS caused reproducible colitis in
mice, characterized by elevated macroscopic colon damage
score and increased MPO activity. The i.c. administration of
CGA (20 mg/kg, two times daily) significantly attenuated
acute TNBS-induced colitis, as demonstrated by decreased
total macroscopic score (2.16±0.27 vs. 3.77±0.50 for
CGA+TNBS- and TNBS-treated mice, respectively)
(Fig. 2a). Moreover, CGA significantly reduced ulcer score
(0.29±0.09 vs. 0.79±0.19 for CGA+TNBS- and TNBS-
treated mice, respectively) (Fig. 2b) and increased mouse co-
lon length compared with TNBS-treated animals (Fig. 2c).
Colon thickness and MPO activity were reduced by i.c. ad-
ministration of CGA, but the differences did not reach statis-
tical significance (Fig. 2d, e, respectively). Histological eval-
uation of colon damage revealed that i.c. CGA significantly
reduced the microscopic score (Fig. 3). Administration of
Fig. 2 CGA (20 mg/kg) injected two times daily i.c. over 3 days
attenuated TNBS-induced colitis in mice. Shown are data for macroscop-
ic scores (a), ulcers score (b), colon length (c), colon thickness (d), and
MPO activity (e) after i.c. administration. $P<0.05, $$P<0.01, as
compared to control (vehicle treated) mice; *P<0.05, **P<0.01, as com-
pared to TNBS-treated animals. Data represent mean±SEM of 7–12mice
per group
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CGA in dose of 20 mg/kg i.c. had no effect on studied param-
eters in control mice.
CGA administered p.o. has anti-inflammatory effect on acute
TNBS-induced colitis in mice
Oral administration of CGA attenuated acute TNBS-induced
colitis in mice, but the effect was weaker than that observed
after i.c. instillation (macroscopic score, 2.82±0.3 vs. 2.16±
0.27 for p.o. and i.c. CGA, respectively, Figs. 4a and 2a; ulcer
score, 0.63±0.15 vs. 0.28±0.09 for p.o. and i.c. CGA, respec-
tively, Figs. 4b and 2b). Furthermore, CGA (20 mg/kg, p.o.,
two times daily) did not have any significant effect on colon
length (Fig. 4c), colon thickness (Fig. 4d), and MPO activity
(Fig. 4e) in TNBS-treated mice. In addition, p.o. administra-
tion of CGA did not attenuate microscopic score (Fig. 5).
Administration of CGA in dose of 20 mg/kg p.o. had no effect
on studied parameters in control mice.
Intracolonic administration of CGA attenuates established
TNBS-induced colitis in mice
The i.c. administration of CGA (20 mg/kg, two times daily)
significantly attenuated established colonic inflammation in
the model of TNBS-induced colitis, as demonstrated by de-
creased total macroscopic score (1.78±0.28 vs. 5.94±0.67 for
CGA+TNBS- and TNBS-treatedmice, respectively) (Fig. 6a).
Fig. 3 Microscopic total damage score were attenuated by injection of
CGA (20 mg/kg, two times daily, i.c.). $$$P<0.001, as compared to
control (vehicle-treated) mice; ***P<0.001 as compared to TNBS-
treated animals. Data represent mean±SEM of 7–12 mice per group
Fig. 4 CGA (20 mg/kg) injected two times daily p.o. over 3 days
attenuated TNBS-induced colitis in mice. Shown are data for macroscop-
ic score (a), ulcer score (b), colon length (c), colon thickness (d), and
MPO activity (e). $P<0.05, $$P<0.01, as compared to control (vehicle-
treated) mice; *P<0.05, as compared to TNBS-treated animals. Data
represent mean±SEM of 7–12 mice per group
Fig. 5 CGA (20 mg/kg) injected two times daily p.o. over 3 days
attenuated TNBS-induced colitis in mice. Shown are data from micro-
scopic total damage score. $$P<0.01, as compared to control (vehicle-
treated) mice. Data represent mean±SEM of 7–12 mice per group
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Moreover, CGA significantly reduced ulcer score (0.69±0.27
vs. 1.12±0.02 for CGA+TNBS- and TNBS-treated mice, re-
spectively) (Fig. 6b) and decreased mouse colon thickness
compared with TNBS-treated animals (Fig. 6d). However,
CGA had no effect on colon length (Fig. 6c). Furthermore,
MPO activity was slightly reduced, but the difference did not
reach statistical significance (Fig. 6e).
CGA administered i.c. did not affect hydrogen peroxide level
in acute TNBS-induced colitis
As shown in Fig. 7, there was an increase in H2O2 level mea-
sured in the colon of TNBS-treated mice versus control (ve-
hicle treated) animals. The i.c. administration of CGA had no
effect on tissue H2O2 level in TNBS-induced colitis (0.51±
0.11 vs. 0.63±0.28 for CGA+TNBS- and TNBS-treated mice,
respectively).
CGA administered i.c. reduced activated NF-κB levels
The i.c. administration of CGA significantly decreased
phospho-p65/p-65 ratio in the colon tissue (0.19±0.01 vs.
0.82±0.16 for CGA+TNBS- and TNBS-treated mice, respec-
tively) (Fig. 8).
Fig. 6 CGA (20 mg/kg) injected two times daily i.c. over 5 days
attenuated established TNBS-induced colitis in mice. Shown are data
for macroscopic score (a), ulcer score (b), colon length (c), colon thick-
ness (d), and MPO activity (e). $$P<0.01, $$$P<0.001 as compared to
control (vehicle-treated) mice; *P<0.05, **P<0.01 as compared to
TNBS-treated animals. Data represent mean±SEM of 7–12 mice per
group
Fig. 7 The effect of CGA (20 mg/kg, i.c., two times daily) on hydrogen
peroxide levels in TNBS-treated mice. Data represent mean±SEM of 7–
12 mice per group
Fig. 8 CGA (20 mg/kg, i.c., two times daily) significantly decreased
phospho-p65/p-65 ratio in the mouse colon tissue. The upper panel
shows results of quantitative analysis and the lower panel shows a
representative blot for protein expression of phosphop65 and p65 in
TNBS- and TNBS+CGA-treated mice. *P<0.05, as compared to
TNBS-treated animals. Data represent mean±SEMof 6–8mice per group
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Discussion
Comprehensive data in the literature show that polyphenols
possess anti-oxidant, anti-carcinogenic, and anti-
inflammatory properties, of which only the first two were
sufficiently explored. CGA, which is one of the most abun-
dant natural polyphenols, has been proven as a potent anti-
oxidant and anti-cancerogenic agent, both in the in vivo and
in vitro studies, but only a few reports focused on its anti-
inflammatory activity in vivo. Hence, the primary goal of this
study was to evaluate the anti-inflammatory effect of CGA
and to investigate the potential mechanism of its action in
the GI tract.
We showed that CGA displayed a significant anti-
inflammatory activity in a well-established mouse model of
experimental colitis, as evidenced by reduction of macroscop-
ic damage score, MPO activity, and inhibition of NF-κB acti-
vation. We also demonstrated that CGA produced anti-
inflammatory effect regardless of the oxidative-stress-related
pathways. Our study, along with previously published reports,
shows that CGA may become a new therapeutic or an attrac-
tive supplement in the treatment of IBD. Furthermore, we
showed that the i.c. administration of CGA not only alleviates
colitis in the acute phase but also has healing effects on
established TNBS-induced colonic inflammation. This indi-
cates that CGA may have both prophylactic and therapeutic
activity and may be used in patients regardless of the current
stage of the disease. Moreover, the literature data support our
observations showing that also other quinic acid derivatives
alleviate chronic colitis (di Paola et al. 2010).
Of note, in a study performed by Ng et al. (2014),
consumption of coffee had a protective effect against UC
development in Asians (adjusted OR 0.51; 95 % CI 0.36
to 0.72; group of 256 UC patients diagnosed between
2011 and 2013 from eight countries in Asia and
Australia vs. 940 controls). Furthermore, the average in-
take of coffee by Americans is 3.1 cups a day; moreover,
a single serving of coffee provides between 20 and
675 mg of CGA depending on type of roast and the
volume consumed (Del Rio et al. 2010). Thus, the dose
of CGA used in this study corresponds to the average
intake consumed by human while drinking coffee.
Noteworthy, we found that CGA is more effective after i.c.
than p.o. administration in the mouse model of colitis, which
speaks for its topical, rather than systemic, application. CGA
is absorbed in its intact form in the stomach and—as products
of hydrolysis, such as caffeic acid—in the small intestine.
Once in the cecum, CGA is fully hydrolyzed into caffeic and
other aromatic acids (Lafay et al. 2006), with questionable
biologic activity. This in turn results in lower concentration
of CGA in inflamed colonic tissue after p.o.—than i.c.—ad-
ministration, which may be the reason for its weaker anti-
inflammatory action.
Immunocyte recruitment and activation are key steps in the
intestinal innate immune response (Korzenik et al. 2005;
Kucharzik et al. 2001; Reaves et al. 2001), and studies with
animal models of colitis highlight the relationship between
immunocyte infiltration and disease severity (Knutson et al.
2013). Here we observed that CGA impaired neutrophil
recruitment and protected colonic tissue against injury, as
evidenced by decreased MPO activity, in line with earlier
studies showing a profound effect of CGA on immune cells.
For example, Ruifeng et al. (2014) demonstrated that CGA
ameliorates damage of mammary tissues by reducing neutro-
phil infiltration. It was also shown that CGA inhibits pro-
inflammatory cytokine release induced by lipopolysaccharide
(LPS) in RAW264.7 murine macrophage-like cells (Shan
et al. 2009), as well as leukocyte influx and levels of IL-4,
IL-5, and TNF-α in serum and bronchoalveolar lavage fluid in
endotoxin and allergic lung inflammation (Zhang et al. 2010).
A critical point in neutrophil migration is their ability to ad-
here to endothelial surface and transfer to inflamed tissues by
means of over-expressed or activated adhesion molecules. A
key role in this process is played by L-selectin located on
neutrophils, along with P- and E-selectin on endothelium. A
recent study conducted by Hebeda et al. (2011) indicates that
CGA treatment blocks L-selectin shedding induced by LPS in
neutrophils obtained from rat peritoneum. Moreover, in that
study, the treatment with CGA inhibited LPS-induced platelet
endothelial cell adhesion molecule 1 (PECAM-1) expression
on neutrophil membranes. Our data suggest that the anti-
inflammatory effect of CGA in the GI tract may also result
from interaction with post-transcriptional mechanisms of ad-
hesion molecule expression (Hebeda et al. 2011).
NF-κB is a key transcription factor involved in promoting
the formation of pro-inflammatory mediators. It is a heterodi-
mer consisting of Rel-family proteins including p65, cRel,
RelB, p50, and p52 (Hoesel and Schmid 2013). Although
NF-κB is indispensable for maintaining immune functions,
its excessive activation leads to stimulation of immune cells,
resulting in inflammation (Li and Verma 2002). Activation of
NF-κB involves phosphorylation of an inhibitory protein IκB,
which binds to NF-κB, followed by liberation of activated
factor, its entry to the nucleus, and binding to the κB site in
DNA (Umezawa 2011). In this study, we investigated the
NF-κB activity by assessing pp65/p65 ratio from colonic tis-
sue homogenates. We found that TNBS caused a significant
activation of NF-κB, as shown by higher pp65/p65 ratio,
which was decreased after CGA treatment. Our observation
is in line with the study by di Paola et al. (2010), in which a
quinic acid derivative, 3,5-dicaffeoyl-4-maloquinic acid, ad-
ministered orally reduced MPO levels and inhibited NF-κB
activity in experimental colitis induced by i.c. instillation of
dinitrobenzenesulphonic acid (DNBS) in rats. In another,
in vitro study, the extract from Cymbopogon citrates, contain-
ing CGA reduced TNF-α levels and NF-κB activity in human
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macrophages in a monocyte culture (Francisco et al. 2013).
Taken together, our study is in line with a growing body of
evidence showing that CGA has impact on various types of
immune cells via NF-κB-dependent pathways. CGAmay thus
be used to restore the function of the imbalanced immune
system, including GI inflammation.
The molecular mechanism of CGA action in alleviating
experimental colitis still requires further research. Recently,
oxidative stress and imbalanced production of free oxygen
species have been implicated in IBD pathogenesis.
Oxidative stress may lead to DNA damage, apoptosis, and
cancer development (Valko et al. 2001, 2007). There are sev-
eral anti-oxidative mechanisms in the GI tract, which include
enzymes like catalase (CAT), superoxide dismutase (SOD),
and glutathione peroxidase (GPx), along with non-enzymatic
scavengers, such as glutathione, transient ions (e.g., Fe2+), or
flavonoids. SOD catalyses the reduction of O2
− to H2O2. In
normal cell metabolism, H2O2 is further reduced by GPx in
the presence of NADPH, but during inflammation, when con-
centration of H2O2 increases, it is reduced by CAT. Recent
studies suggest that peripheral immune cells in patients with
active CD have higher SOD activity and H2O2 production
(Beltran et al. 2010). It has also been shown that CGA may
be responsible for inhibition of H2O2-induced apoptotic neu-
ronal death (Kim et al. 2012). In addition, Feng et al. (2005)
suggested that CGA may have protective properties against
environmental carcinogen-induced carcinogenesis via upreg-
ulation of cellular anti-oxidant enzymes and suppression of
ROS-mediated NF-κB activation. Another study showed that
CGA was effective in protecting PC12 cells against methyl-
mercury (MeHg)-induced damage through decrease of GPx
activity and GSH levels (Li et al. 2008). In our study, H2O2
levels were increased inmicewith TNBS-induced colitis com-
pared to control. However, topical administration of CGA did
not reduce the amount of H2O2. The possible explanation is
that the dose of CGAwas insufficient to produce any effect on
high levels of free radicals resulting from inflammatory pro-
cesses in the mouse colon (Shi et al. 2011). We thus hypoth-
esized that CGAmay alter other anti-oxidative pathways, such
as inhibition of lipid peroxidation, reduction of DNA damage,
or increase of nitric oxide scavenging activity, which may
need further confirmation.
Conclusion
CGA has anti-inflammatory properties in the mouse model of
colitis through the reduction of neutrophil infiltration and in-
hibition of NF-κB-dependent pathways, but not the stimula-
tion of the oxidative stress protection mechanism. Our results
suggest that CGA has the potential to become a valuable sup-
plement for the therapy of inflammatory GI diseases.
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